Holen Sie sich die Stockscreener-App
70.50
2.57%
-1.81
Schlusskurs vom Vortag:
$72.31
Offen:
$71.19
24-Stunden-Volumen:
196.40K
Relative Volume:
0.21
Marktkapitalisierung:
$4.83B
Einnahmen:
-
Nettoeinkommen (Verlust:
$-146.66M
KGV:
-25.60
EPS:
-2.7541
Netto-Cashflow:
$-133.21M
1W Leistung:
+1.97%
1M Leistung:
+13.39%
6M Leistung:
+86.03%
1J Leistung:
+124.15%
1-Tages-Spanne:
$69.91
$72.92
1-Wochen-Bereich:
$66.00
$74.09
52-Wochen-Spanne:
$26.20
$84.56
Apogee Therapeutics Inc Stock (APGE) Company Profile
Firmenname
Apogee Therapeutics Inc
Sektor
Branche
Telefon
650-394-5230
Adresse
221 CRESCENT ST., WALTHAM
Compare APGE vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
APGE
Apogee Therapeutics Inc
|
70.68 | 4.94B | 0 | -146.66M | -133.21M | -2.7541 |
|
VRTX
Vertex Pharmaceuticals Inc
|
465.23 | 121.40B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
765.38 | 83.25B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
725.98 | 46.39B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
327.64 | 43.41B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
292.98 | 33.09B | 5.36B | 287.73M | 924.18M | 2.5229 |
Apogee Therapeutics Inc Stock (APGE) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-01-22 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2026-01-07 | Eingeleitet | Wolfe Research | Peer Perform |
| 2025-12-17 | Eingeleitet | Stephens | Overweight |
| 2025-12-10 | Eingeleitet | Deutsche Bank | Buy |
| 2025-11-03 | Eingeleitet | Craig Hallum | Buy |
| 2025-10-21 | Eingeleitet | Mizuho | Outperform |
| 2025-09-25 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2025-07-07 | Bestätigt | BTIG Research | Buy |
| 2025-03-13 | Eingeleitet | Citigroup | Buy |
| 2024-11-25 | Eingeleitet | Canaccord Genuity | Buy |
| 2024-05-10 | Eingeleitet | BofA Securities | Buy |
| 2023-12-20 | Eingeleitet | BTIG Research | Buy |
| 2023-08-08 | Eingeleitet | Guggenheim | Buy |
| 2023-08-08 | Eingeleitet | Jefferies | Buy |
| 2023-08-08 | Eingeleitet | Stifel | Buy |
| 2023-08-08 | Eingeleitet | TD Cowen | Outperform |
| 2023-08-08 | Eingeleitet | Wedbush | Outperform |
Alle ansehen
Apogee Therapeutics Inc Aktie (APGE) Neueste Nachrichten
Rafferty Asset Management LLC Acquires 23,585 Shares of Apogee Therapeutics Inc. $APGE - MarketBeat
Apogee Therapeutics (APGE) Gets a Buy from Mizuho Securities - The Globe and Mail
Apogee Therapeutics Teases 52-Week Zumi Durability Data, Phase III Path at TD Cowen Conference - Yahoo Finance
Is Rising R&D Spend And New Equity Shelf Altering The Investment Case For Apogee Therapeutics (APGE)? - Yahoo Finance
Apogee Therapeutics (APGE) Stock Analysis: Exploring a 47.76% Potential Upside in the Biotech Sector - DirectorsTalk Interviews
Apogee Therapeutics (NASDAQ:APGE) Price Target Raised to $95.00 - MarketBeat
RBC Lowers Price Target on Apogee Therapeutics to $82 From $83, Keeps Sector Perform, Speculative Risk - marketscreener.com
Apogee Therapeutics Stock: Clinical-Stage Risks, Unproven Pipeline, and Uncertain Path to Profitability - TipRanks
Decoding Apogee Therapeutics Inc (APGE): A Strategic SWOT Insigh - GuruFocus
RBC Capital lowers Apogee Therapeutics stock price target on dosing outlook By Investing.com - Investing.com Australia
RBC Capital lowers Apogee Therapeutics stock price target on dosing outlook - Investing.com
Key facts: Apogee Therapeutics posts $285.6M loss; plans Phase 3 trial - TradingView
APGE Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Apogee Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com
Apogee Therapeutics Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Wedbush Adjusts Price Target on Apogee Therapeutics to $95 From $90, Maintains Outperform Rating - marketscreener.com
APOGEE THERAPEUTICS ($APGE) Releases Q4 2025 Earnings - Quiver Quantitative
Apogee Therapeutics (NASDAQ:APGE) Releases Earnings Results, Beats Expectations By $0.02 EPS - MarketBeat
APGE: Strong pipeline progress and robust cash reserves position for key data and trial milestones in 2026 - TradingView
Apogee Therapeutics 2025 10-K: $0 Revenue; EPS $(4.22) - TradingView
Apogee Therapeutics (NASDAQ: APGE) advances long-acting AD biologics - Stock Titan
Apogee Therapeutics Provides Pipeline Progress and Reports Full Year 2025 Financial Results - ChartMill
Precision Trading with Apogee Therapeutics Inc. (APGE) Risk Zones - Stock Traders Daily
JPMorgan Chase & Co. Purchases 417,161 Shares of Apogee Therapeutics Inc. $APGE - MarketBeat
APGE SEC FilingsApogee Therapeutics Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Apogee Therapeutics Stock Up 100% as Fund Lifts Stake to $28 Million - AOL.com
Apogee Therapeutics Stock Up 100% as Fund Lifts Stake to $28 Million - The Motley Fool
Apogee Therapeutics, Inc. (APGE) Stock Analysis: A Promising Biotech with Nearly 50% Upside Potential - DirectorsTalk Interviews
Apogee Therapeutics to Participate in Upcoming March Conferences - The Manila Times
Biotech roadshow: Apogee Therapeutics plans three March conferences - Stock Titan
Apogee Therapeutics (APGE) Expected to Announce Earnings on Monday - Defense World
Apogee Shares Up Nearly 100% in 12 Months, and This $62 Million Buy Signals Ongoing Conviction - Yahoo Finance
Aberdeen Group plc Takes Position in Apogee Therapeutics Inc. $APGE - MarketBeat
RBC Capital Initiates Coverage of Apogee Therapeutics (APGE) With an Outperform Rating - MSN
Apogee Therapeutics Inc. (NASDAQ:APGE) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat
What is Apogee Therapeutics Inc. s 5 year growth outlookJuly 2025 Rallies & Stock Market Timing Techniques - mfd.ru
End of Apogee (APGE) drug collaboration leads to revised analyst expectations - MSN
Apogee Therapeutics Rings the Closing Bell - Nasdaq
End of Apogee (APGE) Drug Collaboration Leads to Revised Analyst Expectations - Finviz
Technical Reactions to APGE Trends in Macro Strategies - Stock Traders Daily
Does Apogee Therapeutics' (APGE) Rebound After Sanofi Amlitelimab Jitters Clarify Its Competitive Position? - Sahm
RTW funds report 4.9% Apogee Therapeutics (APGE) ownership stake - Stock Titan
Is Apogee Therapeutics (APGE) Now Defined by Its IL-13/OX40L Positioning Against Sanofi? - Yahoo Finance
Here is Why Apogee Therapeutics (APGE) Appears Attractive - Yahoo Finance
CEO Moves: What is Apogee Therapeutics Inc. s 5 year growth outlook2025 Market WrapUp & Weekly Top Gainers Trade List - mfd.ru
Apogee Stock Jumps 87% in One Year as This Biotech Fund Lifts Stake to $93 Million - Yahoo Finance
Michael Thomas Henderson Sells 20,000 Shares of Apogee Therapeutics (NASDAQ:APGE) Stock - MarketBeat
CEO Michael Henderson Sells 20,000 Shares of Apogee Therapeutics Inc - GuruFocus
Apogee Therapeutics CEO Sells 20,000 Shares - TradingView
What’s the beta of Apogee Therapeutics Inc. stockTrade Volume Report & Technical Pattern Alert System - mfd.ru
Apogee Therapeutics touts quarterly-to-biannual AD dosing shift, expands asthma ambitions at conference - MarketBeat
Finanzdaten der Apogee Therapeutics Inc-Aktie (APGE)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.50%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):